Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.
J Clin Endocrinol MetabHuang J, Su A, Yang J, Zhuang W, Li Z.
europepmc +1 more source
Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients. [PDF]
Pediatr NephrolKishk OA +4 more
europepmc +1 more source
Has risk management plan system influenced the speed of package insert revisions in Japan? [PDF]
Front Med (Lausanne)Kameyama N, Hosaka A, Maeda H.
europepmc +1 more source
Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation. [PDF]
Ther Adv Drug SafLomeli-Silva A +4 more
europepmc +1 more source
Overview of global monitoring systems for the side effects and adverse events associated with medicinal cannabis use: a scoping review using a systematic approach. [PDF]
BMJ OpenWang RQ, Bonomo YA, Hallinan CM.
europepmc +1 more source
Navigating Oncology Clinical Trials: From Drug Development to Delivery. [PDF]
Clin J Oncol NursBourgeois J, Goodman MS, Braga C.
europepmc +1 more source
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. [PDF]
Alzheimers Res TherIrizarry M +3 more
europepmc +1 more source
The FDA and the Tort System: Postmarketing Surveillance, Compensation, and the Role of Litigation [PDF]
, 2005 Struve, Catherine T
core +1 more source
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. [PDF]
Alzheimers Res TherDonati M +4 more
europepmc +1 more source
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. [PDF]
Am J Clin DermatolHu W, Thornton M, Livingston RA.
europepmc +1 more source